KAROLINSKA DEVELOPMENT AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.628 SEK | -0.61% |
|
+0.49% | -4.12% |
| Apr. 26 | Karolinska Development AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 16 | Karolinska Development AB Announces That Björn Cochlovius Has Declined Re-Election | CI |
Presenter SpeechJim Van Heusden (Executives)Thank you, and welcome all this morning to the pre...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, womenâs health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Companyâs pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.
Calendar
2024-08-30
- Q2 2024 Earnings Release
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.12% | 41.3M | |
| -5.30% | 182B | |
| +3.50% | 114B | |
| -3.30% | 68.38B | |
| +6.36% | 52.46B | |
| +7.92% | 44.25B | |
| +7.52% | 43.55B | |
| +25.36% | 32.69B | |
| +17.85% | 26.73B | |
| -0.31% | 25.79B |
- Stock Market
- Equities
- KDEV Stock
- News Karolinska Development AB
- Transcript : Karolinska Development AB, Q4 2016 Earnings Call, Mar 01, 2017